Effects of a New Antithrombotic Drug GRS, a Soluble Guanylate Cyclase Stimulator, on Endothelial Dysfunction in Rats with Myocardial Infarction

• DOI: 10.1007/s10517-022-05461-y
• Publication Date: 2022-05-02T18:02:42Z
• Authors: V. V. Bykov; V. I. Smol’yakova; G. A. Chernysheva; O. I. Aliev; A. M. Anishchenko; A. V. Sidekhmenova; O. I. Dunaeva; S. A. Stankevich; V. A. Khazanov
• Keywords: 0301 basic medicine; 0303 health sciences; 03 medical and health sciences; Soluble Guanylyl Cyclase; 0302 clinical medicine; Fibrinolytic Agents; Guanylate Cyclase; Vasodilator Agents; Myocardial Infarction; Animals; Humans; Nitric Oxide; Rats

New antithrombotic drug GRS, a soluble guanylate cyclase stimulator, after repeated administration in a dose of 10 mg/kg alleviates the symptoms of endothelial dysfunction in rats with myocardial infarction; it restores antiplatelet activity of the blood vessel wall and vasodilatory function of the endothelium without producing significant effect on endothelium-independent vasodilation. GRS also has direct antiaggregant and antihypertensive effects in therapeutic doses. The obtained data suggest that GRS can be therapeutically useful in patients with cardiovascular diseases accompanied by endothelial dysfunction.